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The hepatocyte paraffin 1 (Hep Par 1) antibody is widely used
as a hepatocyte marker, recognizing carbamoyl phosphate
synthetase 1 (CPS1), an essential component of the urea
cycle. Various missense, nonsense, and frameshift mutations
occur in theCPS1gene. In neonatal patientswith homozygous
CPS1deficiency (CPS1D), urea cycle defectswith resulting se-
vere hyperammonemia can be fatal, though liver transplanta-
tion provides a complete cure for CPS1D. We performed Hep
Par 1 immunostaining in the explanted livers of 10 liver trans-
plant patients with CPS1D. Seven were negative for Hep Par
1 in the hepatocytes and the other three showed normal
diffuse granular cytoplasmic staining. As expected, all three
Hep Par 1-positive patients had at least one missense muta-
tion, and all four patientswho had only nonsense or frameshift
mutations were Hep Par 1-negative. The other three patients
were unexpectedly negative for Hep Par 1, even though each
had one missense mutation. These results suggest that
CPS1D can be related to the loss of Hep Par 1 reactivity due
to the lossof protein production, a one amino acid substitution
resulting in an abortive protein product, or both. Hep Par 1
immunohistochemistry can be used as a simple method to
confirm CPS1D.
Key words: CPS1, Hep Par 1, liver transplantation
Hepatocyte paraffin 1 (Hep Par 1, clone OCH1E5.2.10) is a
mouse monoclonal antibody generated using extracts from
formalin-fixed liver tissue.1 The antibody reacts with the mito-
chondria of hepatocytes and small intestine epithelium, but
not with that of most other tissues.1,2 Therefore, this antibody
has been used as a marker for hepatocytes and hepatocellular
neoplasms in surgical pathology practice. More than a decade
after the development of the monoclonal antibody, the antigen
was identified as carbamoyl phosphate synthetase 1 (CPS1).3
CPS1 is the rate-limiting enzyme in the urea cycle, synthesizing
carbamoyl phosphate from bicarbonate, adenosine triphos-
phate and ammonia.4 This enzyme is the most abundant
protein in liver mitochondria, accounting for about 20 % of the
total mitochondrial proteins.4 This enzyme is composed of an
intersubunit interacting domain, a glutaminase domain, a bicar-
bonate phosphorylation domain, a domain of unknown function,
a carbamate phosphorylation domain and an N-acetyl-L-
glutamate binding domain,5 which the Hep Par 1 antibody
recognizes is not known. CPS1 deficiency (CPS1D; OMIM
#237300) is an autosomal recessive disorder characterized
by hyperammonemia ranging from neonatally lethal to
environmentally-induced adult-onset disease.4,5 In newborn
patients, hyperammonemiamanifests after feeding commence-
ment, with symptoms such as vomiting, hypothermia, somno-
lence, lethargy, apnea, seizure, or coma. Though the initial
medical treatment of CPS1D consists of protein restriction and
medications such as sodium phenylbutyrate, only liver trans-
plantation can offer complete avoidance of recurrent
hyperammonemia and prevent serious neurological damage.6
Various types of mutations causing CPS1D have been reported,
but missense mutations are the most frequently observed.5
Other mutations include small deletions, splice site changes,
nonsense mutations, and small insertions.5 To our knowledge,
Hep Par 1 immunoreactivity has not been studied in the livers
of patients with CPS1D; therefore, the aim of our study was to
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examine Hep Par 1 immunoreactivity in the livers of patients with
CPS1D. In addition, we also investigated Arginase-1 immunore-
activity. The antigen is a binuclear manganese metalloenzyme
located downstream of CPS1 in the urea cycle.4
MATERIALS AND METHODS
Pathological specimens
Ten liver tissue samples from patients who were clinically diag-
nosedwith CPS1Dand underwent liver transplantation at Kyoto
University Hospital (Cases #5, #9, and #10) or the National
Center for Child Health and Development (Cases #1–#4,
#6–#8) between 2006 and 2013 were obtained for this study.
Informed consent for genetic testing was obtained from the
parents of all patients, and the confidentiality of results was
guaranteed. A pericapsular area of liver tissues (wedge biopsy)
was taken fromeach donor during the Living Donor Liver Trans-
plantation (LDLT), and these samples were used as positive
controls. There was no pre-transplantation biopsy of the
donors. Clinical information on the patients is summarized in
Table 1.
Mutational analysis
Genomic DNA was isolated from the peripheral blood of pa-
tients before the operation. PCR amplification was performed
on the DNA as previously reported.6
Immunohistochemical analysis
Representative sections were prepared from formalin-fixed
paraffin-embedded tissue blocks. Immunohistochemistry was
performed using Benchmark ULTRA (Ventana Medical Sys-
tems, Roche Diagnostics, Indianapolis, IN, USA) with diamino-
benzidine as a chromogen, followed by light counterstaining
with hematoxylin. A monoclonal mouse Hep Par 1 antibody
(clone OCH1E15, 1:200 dilution, DAKO, Glostrup, Denmark)
and a rabbit polyclonal Arginase-1 antibody (1:2500 dilution,
SIGMA, St Louis, MO) were used. Optimal staining was
achieved after microwave pretreatment (60 min; 98 °C; CC1
buffer [10 mmol/L], pH 8.0) for antigen retrieval. Hep Par 1
exhibits a granular cytoplasmic staining pattern. The staining
results were categorized into two groups. Hepatocytes with
granular staining at low power were considered “positive,” and
hepatocytes without granular staining at any power field were
considered “negative.” In case of Arginase-1 staining, nuclear




All samples (Cases #1–10) from the 10 neonatal onset type
CPS1D patients were analyzed. Detected mutations are sum-
marized in Table 2. The mutations found in Cases #1–5 have
been reported previously.6 In total, 12 mutation types were
detected in the CPS1 gene, including 7 missense mutations, 3
nonsense mutations, and 2 frameshift mutations. Four of the 7
missense mutations (c.697C > T, c.2002C > T, c.3540G >
A/c.3683G > C, and c.446 T > C) were previously unreported.
Time-zero biopsy and donor liver (each 10 cases, total 20 sam-
ples) samples were evaluated by Hep Par 1 immunostaining.
All control samples tested positive for Hep Par 1 (data not
shown). Of the explant samples taken from CPS1D patients,
three were positive for Hep Par 1, and 7 were negative. Repre-
sentative images are shown in Fig. 1. Scattered granular stain-
ing of Hep Par 1 in sinusoidal cells was observed in the sample
from Case #10 (Fig. 1). Hep Par 1-positive cases (Cases #2,
#4, and #5) had missense mutations in at least one allele. In
contrast, the other three cases (Cases #3, #7 and #10) with at
least one allele containing a missense mutation were Hep Par
1-negative. The other four cases (Cases #1, #6, #8, and #9)
without missense mutations had nonsense and/or frameshift
mutations in both alleles, and were negative for Hep Par 1.
We could not find any relationship between clinical characteris-
tics and immunoreactivity of Hep Par 1.
We also examined Arginase-1 immunoreactivity using Case
#5, #9 and #10. In all-examined cases, Arginase-1 had showed
positive staining.
DISCUSSION
Asexpected, samples frompatients with nonsense and/or frame-
shift mutations in both alleles were Hep Par 1-negative;
nonsense-mediatedmRNAdecay (NMD) could explain these re-
sults. NMD is also known as mRNA surveillance, and is one of
several post-transcriptional mechanisms that control the quality
of mRNA function.7 NMD prevents the production of truncated
proteins that could function in dominant-negative or other
Table 1 Patients with carbamoyl phosphate 1 deficiency
Case Age at LTx(month) Gender Donor Reference
#1 4 F Mother 6
#2 6 F Father 6
#3 8 F Mother 6
#4 10 F Mother 6
#5 21 F Mother 6
#6 6 F Mother Unreported
#7 7 F Father Unreported
#8 6 M Father Unreported
#9 9 M Father Unreported
#10 9 M Father Unreported
LTx, liver transplantation.
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deleterious mechanisms by eliminating abnormal transcripts that
prematurely terminate translation. Some nonsense or frameshift
CPS1 mutations, including p.R1261X (Case #9), were reported
to form premature termination codons, and the mutated mRNAs
are subsequently eliminated by theNMDpathway.8 In the current
case series, p.510fs514X was found in three cases. To our best
knowledge, this type of mutation has been reported in six cases
including the current cases.6 All these cases were Japanese pa-
tients, and 6 of 30 cases (20 %) had this type of CPS1 mutation
among Japanese CPS1D patients reported. However, this
mutationwas not reported in any non-JapaneseCPS1Dpatients.
p.510fs514X mutation is located exon 14, encoding a region of
the bicarbonate phosphorylation domain.5 We suppose that the
CPS1 mRNA with p.510fs514X mutation would be eliminated
by NMD, as is the case of p.R1261X mutation.
HepPar 1 staining patterns in caseswithmissensemutations
in at least one of the alleles varied. The p.R850H (Case #2) and
p.R587H (Case #5) mutations were recognized by Hep Par 1.
The p.P668S mutation or CPS1 with p.T1406 N mutation or
both was also recognized by Hep Par 1. These results make
Table 2 CPS1 mutations and Hep Par 1 immunostaining patterns
Case Mutations
cDNA Allele 1
(amino acid; pattern of mutation)
cDNA Allele 2
(amino acid; pattern of mutation) Hep Par 1 staining Arginase-1
#1 Homozygous c.1528delG (p.510fs514X; Frameshift) c.1528delG (p.510fs514X; Frameshift) Negative N.E.
#2 Heterozygous c.1528delG (p.510fs514X; Frameshift) c,2549G > A (p.R850H; Missense) Positive N.E.
#3 Heterozygous c.697C > T (p.R233C; Missense) c.1528delG (p.510fs514X; Frameshift) Negative N.E.
#4 Heterozygous c.1030 A > G & c.1032C > T/c.4217C > A
(p.T344 A/p.T1406 N; Missense/Missense)
c.2002C > T(p.P668S; Missense) Positive N.E.
#5 Heterozygous c.1760G > A (p.R587H; Missense) c.2494delGinsAA (p.832fs836X;
Frameshift)
Positive Positive
#6 Heterozygous c.2359C > T (p.R787X; Nonsense) c.3093C > A (p.Y1031X; Nonsense) Negative N.E.
#7 Heterozygous c.1528delG (p.fs514X; Frameshift) c.3540G > A/c.3683G > C
(p.A1180 T/p.R1228P; Missense/Missense)
Negative N.E.
#8 Homozygous c.1528delG (p.510fs514X; Frameshift) c.1528delG (p.510fs514X; Frameshift) Negative N.E.
#9 Heterozygous c.1528delG (p.510fs514X; Frameshift) c.3784C > T (p.R1261X; Nonsense) Negative Positive





Figure 1 Representative images of the livers of
patients with carbamoyl phosphate 1 deficiency.
The left column shows H&E staining and the mid-
dle column shows Hep Par 1 immunostaining.
Case #1 and Case #9 were completely negative
for Hep Par 1; Case #5 shows normal hepatocyte
granular staining. The hepatocytes in Case #10
were negative for Hep Par 1, and only some sinu-
soidal cells (Kupffer cells) showed immunoreac-
tivity. The right column shows Arginase-1
immunostaining. Case #5, Case #9 and Case
#10 were positive for Arginase-1.
Hep Par 1 immunostaining for CPS1 deficiency 3
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sense since CPS1 proteins with only one amino acid substitu-
tion may be fully expressed. However, the p.R233C (Case #3)
and p.A1180 T/p.R1228P (Case #7) mutations were not recog-
nized by Hep Par 1. These amino acid substitutions may cause
a dramatic change in the sites recognized by Hep Par 1. In
Case #10, the hepatocytes were Hep Par 1-negative, but the
sinusoidal cells were aberrantly Hep Par 1-positive. Although
the mechanism is unclear, CPS1 with p.L149S mutation may
excrete CPS1 for processing in Kupffer cells.
Immunohistochemical analysis can be more easily achieved
compared to mutational analysis. The results of this study
provide evidence for the usefulness of immunohistochemistry
to detect certainmutations causingCPS1D.CPS1 is expressed
in the small intestinal epithelium in addition to hepatocytes.2
Biopsy of the small intestine may be easier than that of the liver,
and one report successfully detected CPS1D in duodenal
samples.9 Therefore, HepPar 1 immunostaining using biopsied
samples from the small intestine or the liver may be helpful for
the diagnosis of CPS1D.
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